← Back to Investors

HealthCap

HealthCap is one of the largest and most experienced European life sciences venture capital firms. Founded in Stockholm, they have a track record spanning nearly three decades of investing in innovative biotech and medtech companies across Europe and globally.

Location
Stockholm, Sweden
Founded
1996
AUM
€2B+
Investment Range
€5M - €50M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c, growth

Investment Thesis

HealthCap invests in life sciences companies developing innovative therapeutics and medical technologies. They focus on companies with strong science, experienced management, and potential for significant value creation through clinical development and commercial success.

Team

Partners / Managing Directors (Health & Bio Focus)

  • Björn Odlander, MD, PhD - Founding Partner
  • Peder Fredrikson, MD, PhD - Founding Partner
  • Johan Kördel, PhD - Partner
  • Staffan Lindstrand - Partner

Other Key Team Members

  • Eugen Steiner, MD, PhD - Partner
  • Jacob Gunterberg - Partner

Focus Areas

  • Therapeutics (oncology, immunology, CNS)
  • Medical devices
  • Diagnostics
  • Nordic life sciences ecosystem
  • European biotech
  • Rare diseases

Notable Exits

  • Cormorant Pharmaceuticals - Acquired by Bristol-Myers Squibb (2016)
  • Algeta - Acquired by Bayer (2014, $2.9B)
  • Orexo - IPO (multiple drugs including Zubsolv)
  • Wilson Therapeutics - Acquired by Alexion (2018, $855M)

Sources